DDW: Full-spectrum preferred over forward-viewing colonoscopy

This article originally appeared here.
Share this content:
DDW: Full-Spectrum Beats Forward-Viewing Colonoscopy
DDW: Full-Spectrum Beats Forward-Viewing Colonoscopy

(HealthDay News) -- Use of a Full-Spectrum Endoscopy (FUSE) colonoscope is associated with increased polyp and adenoma detection rates and lower miss rates, compared with traditional forward-viewing (TFV) colonoscope, according to a study presented at the annual Digestive Disease Week, held from May 18 to 21 in Orlando, Fla.

Ian M. Gralnek, M.D., of the Technion-Israel Institute of Technology in Haifa, and colleagues conducted a multicenter study to determine incremental polyp and adenoma detection rates and miss rates of colonoscopy during same-day back-to-back tandem colonoscopies. One hundred eighty-three individuals referred for colorectal cancer screening were randomly assigned to undergo colonoscopy starting with a TFV colonoscope or a FUSE colonoscope.

The researchers found that, for the 88 individuals who received TFV as the initial colonoscopy, 49 polyps were detected in 36 individuals. An additional 39 polyps were detected in 29 subjects on subsequent FUSE colonoscopy, for an incremental polyp detection rate of 32.9 percent in per-patient analysis and 79.6 percent in per-polyp analysis. In the same cohort, using FUSE colonoscopy, the incremental adenoma detection rate was 17.1 percent in per-patient analysis and 75 percent in per-adenoma analysis. For the 95 patients who received FUSE as the initial colonoscopy examination, the polyp miss rate was 9.4 percent, compared with 44.3 percent for TFV colonoscopy. The adenoma miss rate was 8.1 percent for FUSE colonoscopy compared with 42.9 percent for TFV colonoscopy.

"It's always our goal to minimize miss rates in colonoscopy," Gralnek said in a statement. "These results show us a way to achieve that and improve the efficacy of colorectal cancer screening and surveillance colonoscopy."

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs